<DOC>
	<DOCNO>NCT00191594</DOCNO>
	<brief_summary>A study patient depression</brief_summary>
	<brief_title>Open-Label Duloxetine Extension Phase Patients Who Have Completed Previous Duloxetine Trials</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Male female patient least 18 year age previously complete satisfactorily Lilly sponsor previous clinical trial , clinically control Duloxetine , judge investigator All female must test negative urine pregnancy test Visit 1 . Females childbearing potential ( surgically sterilize menarche 1 year postmenopausal ) must agree utilize medically acceptable reliable mean birth control determine investigator study . Women pregnant breastfeeding may participate study . Must sign inform consent document ( ICD ) . Have receive treatment within last 30 day drug ( include study drug ) receive regulatory approval indication time study entry . Patients enter optional tapering period previous study . In opinion investigator , patient judge serious suicidal risk . Treatment MAOI within 14 day prior Visit 1 potential need use MAOI study within 5 day discontinuation study drug . Any patient previously experience serious adverse event take duloxetine unless approve Lilly Physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>